PMID- 37150013
OWN - NLM
STAT- MEDLINE
DCOM- 20230601
LR  - 20230601
IS  - 1878-1705 (Electronic)
IS  - 1567-5769 (Linking)
VI  - 119
DP  - 2023 Jun
TI  - Combination therapy with immune checkpoint inhibitors in recurrent or metastatic 
      squamous cell carcinoma of the head and neck: A meta-analysis.
PG  - 110270
LID - S1567-5769(23)00592-1 [pii]
LID - 10.1016/j.intimp.2023.110270 [doi]
AB  - OBJECTIVES: To evaluate the efficacy and safety of immune checkpoint inhibitor 
      (ICI) combination therapy in the first-line treatment for recurrent or metastatic 
      squamous cell carcinoma of the head and neck (R/M-SCCHN). METHODS: We conducted a 
      meta-analysis between ICI combination therapy and standard of care (SOC) 
      treatment (chemotherapy with or without cetuximab) in R/M-SCCHN based on 
      randomized controlled trials (RCTs). The outcomes were overall survival (OS), 
      progression-free survival (PFS), objective response rate (ORR), and adverse 
      events (AEs). RESULTS: Five RCTs involving 2576 patients were included in the 
      analysis. Compared with SOC, PD-1 inhibitor plus chemotherapy significantly 
      improved OS (hazard ratio [HR], 0.73, 95 % CI 0.62-0.87, p = 0.0004), PFS (HR, 
      0.65, 95 % CI 0.43-0.99, p = 0.04) and ORR (risk ratio [RR], 1.10; 95 % CI 
      1.01-1.19, p = 0.02) of patients, while double-agent immunotherapy could not 
      improve either the outcome of OS, PFS, or ORR (all p > 0.05). In safety analyses, 
      combination immunotherapy showed similar risks of grade 3 or higher 
      treatment-related AEs (RR, 0.79, 95 % CI 0.56-1.11, P = 0.17) and 
      treatment-related deaths (RR, 1.16, 95 % CI 0.65-2.07, P = 0.63) compared to SOC. 
      CONCLUSIONS: Compared with SOC, PD-1 inhibitor plus chemotherapy enhanced OS, 
      PFS, and ORR in the first-line treatment for patients with R/M-SCCHN, but 
      double-agent immunotherapy showed no more benefit for these patients.
CI  - Copyright (c) 2023 Elsevier B.V. All rights reserved.
FAU - Chen, Long
AU  - Chen L
AD  - Otorhinolaryngology Department, The Third Affiliated Hospital of Guangxi Medical 
      University, Nanning, Guangxi, China. Electronic address: 18978143428@163.com.
FAU - Mo, Dun-Chang
AU  - Mo DC
AD  - Radiotherapy Department, The Third Affiliated Hospital of Guangxi Medical 
      University, Nanning, Guangxi, China.
FAU - Hu, Min
AU  - Hu M
AD  - Otorhinolaryngology Department, The Third Affiliated Hospital of Guangxi Medical 
      University, Nanning, Guangxi, China.
FAU - He, Wei
AU  - He W
AD  - Otorhinolaryngology Department, The Third Affiliated Hospital of Guangxi Medical 
      University, Nanning, Guangxi, China.
FAU - Yang, Qiang-Wei
AU  - Yang QW
AD  - Otorhinolaryngology Department, The Third Affiliated Hospital of Guangxi Medical 
      University, Nanning, Guangxi, China.
FAU - Tang, Jun
AU  - Tang J
AD  - Otorhinolaryngology Department, The Third Affiliated Hospital of Guangxi Medical 
      University, Nanning, Guangxi, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
DEP - 20230505
PL  - Netherlands
TA  - Int Immunopharmacol
JT  - International immunopharmacology
JID - 100965259
RN  - 0 (Immune Checkpoint Inhibitors)
RN  - PQX0D8J21J (Cetuximab)
SB  - IM
MH  - Humans
MH  - Squamous Cell Carcinoma of Head and Neck/drug therapy
MH  - Immune Checkpoint Inhibitors/therapeutic use
MH  - Cetuximab
MH  - Combined Modality Therapy
MH  - *Head and Neck Neoplasms/drug therapy
MH  - *Lung Neoplasms/drug therapy
MH  - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
OTO - NOTNLM
OT  - Immune checkpoint inhibitor
OT  - Immunotherapy
OT  - Meta-analysis
OT  - PD-1/PD-L1
OT  - Squamous cell carcinoma of the head and neck
COIS- Declaration of Competing Interest The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2023/05/08 00:41
MHDA- 2023/06/01 06:42
CRDT- 2023/05/07 18:05
PHST- 2023/03/22 00:00 [received]
PHST- 2023/04/19 00:00 [revised]
PHST- 2023/04/28 00:00 [accepted]
PHST- 2023/06/01 06:42 [medline]
PHST- 2023/05/08 00:41 [pubmed]
PHST- 2023/05/07 18:05 [entrez]
AID - S1567-5769(23)00592-1 [pii]
AID - 10.1016/j.intimp.2023.110270 [doi]
PST - ppublish
SO  - Int Immunopharmacol. 2023 Jun;119:110270. doi: 10.1016/j.intimp.2023.110270. Epub 
      2023 May 5.